Novo Nordisk "selective" about potential obesity acquisitions, says director
Novo Development Director, Martin Holst Lange, reports an increased general interest in obesity candidates in the industry, but denies suggestions Novo is hoovering up the market.
Novo Nordisk typically investigates hundreds of candidates before an acquisition becomes a reality, says Director of Development, Martin Holst Lange, in an interview with MedWatch about the company’s obesity treatment pipeline.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly and Fauna Bio sign obesity deal
For subscribers
